Prof John Deanfield, the director of the National Institute for Cardiovascular Outcomes Research and the lead author of the study, said the findings showed that the medication should be routinely prescribed to treat cardiovascular illnesses, and that millions of people across the UK could be taking the medication in the next few years
Xu M, Wu HY, Liu H, Gong N, Wang YR, Wang YX (2017) Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors
In addition, GLP-2, an intestinotrophic hormone with clinical application for short bowel syndrome, reduces bone resorption
Transitioning from semaglutide to tirzepatide is becoming increasingly common as patients and providers explore options that may offer broader metabolic support